Business Context and Reporting Period
This Form 6-K filing incorporates the GlaxoSmithKline (GSK) Annual Review for the fiscal year ended December 31, 2005. The report was filed on April 5, 2006. GSK operates globally in pharmaceuticals, vaccines, and consumer healthcare. The company reported its financial results under International Financial Reporting Standards (IFRS) for the first time in 2005, with comparative figures restated accordingly.
Key Financial Metrics
| Metric | 2005 Value | 2004 Value | Growth (CER) |
|---|---|---|---|
| Total Turnover | £21.7 billion | £20.0 billion | 7% |
| Pharmaceutical Turnover | £18.7 billion | £17.1 billion | 8% |
| Consumer Healthcare Turnover | £3.0 billion | £2.9 billion | 2% |
| Operating Profit | £6.9 billion | £5.8 billion | 16% |
| Operating Margin | 31.7% | 28.8% | +2.9 pts |
| Profit After Taxation | £4.8 billion | £4.0 billion | 17% |
| Earnings Per Share (Basic) | 82.6 pence | 68.1 pence | 18% |
| Free Cash Flow | £4.7 billion | £3.7 billion | 26% |
| Dividend Per Share | 44 pence | 42 pence | 2 pence increase |
Balance Sheet Highlights: Total assets stood at £27.2 billion, with shareholders' equity at £7.3 billion. Cash and cash equivalents totaled £4.2 billion at year-end.
Material Changes vs. Prior Period
- Revenue Growth: Turnover grew 7% at constant exchange rates (CER), driven primarily by the Pharmaceuticals division (+8%) and Vaccines (+15%). Consumer Healthcare growth was modest at 2%.
- Profitability: Operating profit margin expanded by 2.9 percentage points to 31.7%, aided by lower legal charges and share-based payment costs, despite increased R&D expenditure.
- Product Performance:
- Respiratory: Seretide/Advair sales grew 22% to £3.0 billion, capturing 33% market share in the US.
- Metabolic: Avandia/Avandamet sales rose 18% to £1.3 billion.
- Vaccines: Sales increased 15% to £1.4 billion, led by Infanrix and new US launches.
- Declines: Central Nervous System (CNS) sales fell 8% due to generic competition for Paxil and Wellbutrin, and supply interruptions at the Cidra plant.
- Acquisitions: GSK invested over £1 billion in 2005 to acquire ID Biomedical, Corixa, and a vaccine plant in Marietta, Pennsylvania, strengthening its flu vaccine capabilities.
Guidance, Outlook, and Risks
Outlook and Guidance
Management anticipates continued strong growth from key products and the vaccines business in 2006. The company forecasts Earnings Per Share (EPS) growth of approximately 10% at constant exchange rates for 2006.
Pipeline Milestones: Seven major product filings are planned for 2006, including Cervarix (cervical cancer vaccine), Rotarix (rotavirus), and Avandaryl (diabetes). Eight major new assets are expected to enter Phase III trials, doubling the late-stage pipeline.
Risks and Contingencies
- Legal Proceedings: GSK is involved in patent litigation regarding generic versions of key products (e.g., Wellbutrin, Seretide, Avandia) and product liability lawsuits. The company is also responding to US government investigations into pricing and marketing practices.
- Tax Disputes: A significant tax dispute exists with the US Internal Revenue Service (IRS) regarding transfer pricing for Glaxo heritage products. The IRS has claimed additional taxes of $4.6 billion plus interest for 1989-2000. GSK estimates a potential unprovided exposure of approximately $11.5 billion for the period 1989-2005 if the IRS methodology is applied to later years. A trial is scheduled to commence in October 2006.
- Manufacturing: Supply interruptions occurred in 2005 at the Cidra, Puerto Rico facility due to FDA inspections. While supply was restored in June 2005, the company is implementing a "Vision Factory" initiative to ensure future operational excellence.
Investor Verification Checklist
- Tax Exposure: Verify the status of the IRS transfer pricing dispute and the adequacy of the current provision against the estimated $11.5 billion potential exposure.
- Supply Chain Resilience: Confirm the long-term resolution of manufacturing issues at the Cidra plant and the impact of the "Vision Factory" initiative on future supply stability.
- Pipeline Execution: Monitor the approval timelines for key 2006 launches, specifically Cervarix and Rotarix, which are critical to the growth outlook.
- Patent Litigation: Track outcomes of patent infringement cases involving core revenue drivers like Seretide/Advair and Avandia.
- US GAAP Reconciliation: Note the significant difference between IFRS and US GAAP earnings due to the treatment of product rights (amortization vs. impairment), which reduces US GAAP EPS to 58.8 pence compared to 82.6 pence under IFRS.